Ссылки
1. Angell M. The Truth about the Drug Companies: how they deceive us and what to do about it. New York: Random House; 2004.
2. Moynihan R., Cassels A. Selling Sickness: how the world’s biggest pharmaceutical companies are turning us all into patients. New York: Nation Books; 2005.
3. Weingart S. N., Wilson R. M., Gibberd R. W., et al. Epidemiology of medical error. BMJ. 2000; 320: 774–7.
4. Starfield B. Is US health really the best in the world? JAMA. 2000; 284: 483–5.
5. Lazarou J., Pomeranz B. H., Corey P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279: 1200–5.
6. Ebbesen J., Buajordet I., Erikssen J., et al. Drug-related deaths in a department of internal medicine. Arch Intern Med. 2001; 161: 2317–23.
7. Archibald K., Coleman R., Foster C. Open letter to UK Prime Minister David Cameron and Health Secretary Andrew Lansley on safety of medicines. Lancet. 2011; 377: 1915.
8. Centers for Disease Control and Prevention. Leading Causes of Death. Available online at: www.cdc.gov/nchs/fastats/lcod.htm (accessed 5 February 2013).
9. Lenzer J. Anticoagulants cause the most serious adverse events, finds US analysis. BMJ. 2012; 344: e3989.
10. Centers for Disease Control and Prevention. Tobacco-Related Mortality. Available online at: www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/tobacco_related_mortality/ (accessed 2 February 2013).
11. Iyer S., Naganathan V., McLachlan A. J., et al. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging. 2008; 25: 1021–31.
12. Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.
13. Rennie D. When evidence isn’t: trials, drug companies and the FDA. J Law Policy. 2007 July: 991–1012.
14. Kassirer J. P. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.
15. Smith R. The Trouble with Medical Journals. London: Royal Society of Medicine; 2006.
16. Brownlee S. Overtreated: why too much medicine is making us sicker and poorer. New York: Bloomsbury; 2007.
17. World Health Organization. World Health Report 2003 – shaping the future. 2003. Available online at: www.who.int/whr/2003/annex_4_en.xls (accessed 20 December 2012).
18. Reinhardt U. E., Hussey P. S., Anderson G. F. U. S. health care spending in an international context. Health Aff (Millwood). 2004; 23: 10–25.
19. Roehr B. Health care in US ranks lowest among developed countries, Commonwealth Fund study shows. BMJ. 2008; 337: a889.
20. Starfield B., Shi L., Grover A., et al. The effects of specialist supply on populations’ health: assessing the evidence. Health Aff (Millwood). 2001 March 15. DOI: 10.1377/hlthaff.w5.97.
21. World Health Organization. The World Medicines Situation. Available online at: http://apps.who.int/medicinedocs/en/d/Js6160e/6.html#Js6160e6. (accessed 6 February 2013).
22. Wealth but not health in the USA. Lancet. 2013; 381: 177.
23. Nolte E., McKee C. M. Measuring the health of nations: updating an earlier analysis. Health Aff (Millwood). 2008; 27: 58–71.
24. Avendano M., Glymour M. M., Banks J., et al. Health disadvantage in US adults aged 50 to 74 years: a comparison of the health of rich and poor Americans with that of Europeans. Am J Public Health. 2009; 99: 540–8.
25. Jachuck S. J., Brierley H., Jachuck S., et al. The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract. 1982; 32: 103–5.
26. Krogsb?ll L. T., J?rgensen K. J., Gr?nh?j Larsen C., et al. General health checks for reducing morbidity and mortality from disease. Cochrane Database Syst Rev. 2012; 10: CD009009.
27. Johnston M. E., Gibson E. S., Terry C. W., et al. Effects of labelling on income, work and social function among hypertensive employees. J Chronic Dis. 1984; 37: 417–23.
28. Butt D. A., Mamdani M., Austin P. C., et al. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med. 2012; 172: 1739–44.
29. Abramson J. Overdo$ed America. New York: HarperCollins; 2004.
30. Oliver M. Let’s not turn elderly people into patients. BMJ. 2009; 338: b873.
31. Cacciotti J., Clinton P. Pharm Exec 50: growth from the bottom up. Pharmaceutical Executive. 2012 May 1. Available online at: www.pharmexec.com/pharmexec/Noteworthy/Pharm-Exec-50-Growth-from-the-Bottom-Up/ArticleStandard/Article/detail/773562 (accessed 17 July 2013).
32. Berwick D. M., Hackbarth, A. Eliminating waste in US health care. JAMA. 2012; 307: 1513–16.
33. Liberati A., Magrini N. Information from drug companies and opinion leaders. BMJ. 2003; 326: 1156–7.
34. Tanne J. H. US healthcare executives hit pay jackpot. BMJ. 2011; 343: d8330.
35. Whelton R. S. Effects of Excessive CEO Pay on U. S. Society. Available online at: www.svsu.edu/emplibrary/Whelton%20article.pdf (accessed 6 November 2007).
36. Schafer A. Biomedical confl icts of interest: a defence of the sequestration thesis – learning from the cases of Nancy Olivieri and David Healy. J Med Ethics. 2004; 30: 8–24.
37. Relman A. A Second Opinion: rescuing America’s health care. New York: Public Affairs; 2007.
38. Krimsky S. Science in the Private Interest: has the lure of profits corrupted biomedical research? Lanham: Rowman & Littlefield; 2003.
39. Braithwaite J. Corporate Crime in the Pharmaceutical Industry. London: Routledge & Kegan Paul; 1984.
40. Goozner M. The $800 Million Pill: the truth behind the cost of new drugs. Berkeley: University of California Press; 2005.
41. Abraham J. Science, Politics and the Pharmaceutical Industry. London: UCL Press; 1995.
42. Day M. MRC says it will invent, develop, and market its own drugs. BMJ. 2007; 334: 1025.
43. Bloemen S., Hammerstein D. Time for the EU to lead on innovation. Health Action International Europe and Trans Atlantic Consumer Dialogue. 2012 April.
44. Bassand J.-P., Martin J., Ryd?n L., et al. The need for resources for clinical research: The European Society of Cardiology calls for European, international collaboration. Lancet. 2002; 360: 1866–9.
45. G?tzsche P. C., Hansen M., Stoltenberg M., et al. Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. Scand J Rheumatol. 1996; 25: 194–9.
46. Relman A. S., Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic. 2002 Dec 16: 27–41.
47. G?tzsche P. C. Blinding during data analysis and writing of manuscripts. Controlled Clin Trials. 1996; 17: 285–90.
48. Borst-Eilers E. Assessing hospital technology in the Netherlands: new treatments are paid for only if they are part of an evaluation. BMJ. 1993; 306: 226.
49. Garattini S., Bertele V. How can we regulate medicines better? BMJ. 2007; 335: 803–5.
50. Liberati A., Traversa G., Moja L. P., et al. Feasibility and challenges of independent research on drugs: the Italian Medicines Agency (AIFA) experience. Eur J Clin Invest. 2010; 40: 69–86.
51. Light D. W., Lexchin J. R. Pharmaceutical research and development: what do we get for all that money? BMJ. 2012; 344: e4348.
52. Knowler W. C., Barrett-Connor E., Fowler S. E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393–403.
53. Ioannidis J. P., Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001; 285: 437–43.
54. Savulescu J., Chalmers I., Blunt J. Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability. BMJ. 1996; 313: 1390–3.
55. Goldbeck-Wood S. Denmark takes a lead on research ethics. BMJ. 1998; 316: 1189.
56. Goldacre B. Bad Pharma. London: Fourth Estate; 2012.
57. Lundh A., Krogsb?ll L. T., G?tzsche P. C. Access to data in industry-sponsored trials. Lancet. 2011; 378: 1995–6.
58. Lundh A., Krogsb?ll L. T., G?tzsche P. C. Sponsors’ participation in conduct and reporting of industry trials: a descriptive study. Trials. 2012; 13: 146.
59. Heran B. S., Wong M. M. Y., Heran I. K., et al. Blood pressure lowering effi cacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2008; 4: CD003823.
60. Directive 2010/84/EU of the European Parliament and of the Council. 2010 Dec 15.
61. G?tzsche P. C., Liberati A., Luca P., et al. Beware of surrogate outcome measures. Int J Technol Ass Health Care. 1996; 12: 238–46.
62. Apolone G., Joppi R., Bertele V., et al. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to fi nd a balance between different pressures. Br J Cancer. 2005; 93: 504–9.
63. Garattini S., Bertele V. Effi cacy, safety, and cost of new anticancer drugs. BMJ. 2002; 325: 269–71.
64. Machin D., Stenning S. P., Parmar M. K. B., et al. Thirty years of Medical Research Council randomized trials in solid tumours. Clin Oncol. 1997; 9: 100–14.
65. Soares H. P., Kumar A., Daniels S., et al. Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA. 2005; 293: 970–8.
66. Kumar A., Soares H., Wells R., et al. Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children’s Oncology Group. BMJ. 2005; 331: 1295–8.
67. Avorn J. Powerful Medicines: the benefi ts, risks, and costs of prescription drugs. New York: Vintage Books; 2005.
68. Rochon P. A., Fortin P. R., Dear K. B., et al. Reporting of age data in clinical trials of arthritis. Deficiencies and solutions. Arch Intern Med. 1993; 153: 243–8.
69. Van Spall H. G., Toren A., Kiss A., et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007; 297: 1233–40.
70. Cerreta F., Eichler H. G., Rasi G. Drug policy for an aging population – the European Medicines Agency’s geriatric medicines strategy. N Engl J Med. 2012; 367: 1972–4.
71. World Medical Association. Ethical Principles for Medical Research Involving Human Subjects. 2008. Available online at: www.wma.net/en/30publications/10policies/b3/ (accessed 17 July 2013).
72. Whitaker R. Anatomy of an Epidemic. New York: Random House; 2010.
73. Strom B. L. How the US drug safety system should be changed. JAMA. 2006; 295: 2072–5.
74. Ray W. A., Stein C. M. Reform of drug regulation – beyond an independent drug-safety board. N Engl J Med. 2006; 354: 194–201.
75. Newman M. Bitter pills for drug companies. BMJ. 2010; 341: c5095.
76. Alsman S. W. [Hidden research led to wrong recommendations about happy pills]. ?konomisk Ugebrev. 2004 May 3.
77. Senate Republican Policy Committee. Legislative Notice No. 13. S. 1082 – The FDA Revitalization Act. Available online at: http://rpc.senate.gov/_fi les/L13S1082FDARevitalizationAct043007KP.pdf (accessed 30 October 2007).
78. Suntharalingam G., Perry M. R., Ward S., et al. Cytokine storm in a phase 1 trial of the anti-CD 28 monoclonal antibody TGN 1412. N Engl J Med. 2006; 355: 1018–28.
79. Lenzer J., Brownlee S. An untold story? BMJ. 2008; 336: 532–4.
80. G?tzsche P. C. Why we need easy access to all data from all clinical trials and how to accomplish it. Trials. 2011; 12: 249.
81. Danish Medicines Agency. [Danish Medicines Agency’s Performance Contract 2007–2010]. Available online at: www.laegemiddelstyrelsen.dk/db/fi larkiv/6653/resultatkontrakt2007_2010.pdf (accessed 15 August 2008).
82. Okie S. Safety in numbers – monitoring risk in approved drugs. N Engl J Med. 2005; 352:1173–6.
83. Carlsen L. T. [A diffi cult balance]. T?nk + Test. 2003; 32: 30–3.
84. Mundy A. Dispensing with the Truth. New York: St. Martin’s Press; 2001.
85. Schwartz L. M., Woloshin S., Welch H. G. Using a drug facts box to communicate drug benefits and harms: two randomized trials. Ann Intern Med. 2009; 150: 516–27.
86. Woloshin S., Schwartz L. M., Welch H. G. Know your Chances: understanding health statistics. Berkely: University of California Press; 2008.
87. Woloshin S., Schwartz L. M. Think inside the box. New York Times. 2011 July 4.
88. Chren M. M., Landefeld C. S. Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994; 271: 684–9.
89. Brennan T. A., Rothman D. J., Blank L., et al. Health industry practices that create confl icts of interest: a policy proposal for academic medical centers. JAMA. 2006; 295: 429–33.
90. Tougaard H., Hundevadt K. [The golden promises of the gynaecologists]. Jyllandsposten. 2004 Jan 18.
91. Fugh-Berman A., McDonald C. P., Bell A. M., et al. Promotional tone in reviews of menopausal hormone therapy after the women’s health initiative: an analysis of published articles. PLoS Med. 2011; 8: e1000425.
92. Singer N. Medical papers by ghostwriters pushed therapy. New York Times. 2009 Aug 4.
93. Rosenberg M. Pfizer’s ghostwritten journal articles are still standing, still bogus. Online Journal. 2010 Feb 23.
94. G?tzsche P. C. Mammography Screening: truth, lies and controversy. London: Radcliffe Publishing; 2012.
95. Conflicts of interest in biomedical research. Canada’s Voice for Academics. 2003; 50: Feb.
96. Elliott C. Pharma goes to the laundry: public relations and the business of medical education. Hastings Cent Rep. 2004; 34: 18–23.
97. Willman D. How a new policy led to seven deadly drugs. Los Angeles Times. 2000 Dec 20.
98. Bindslev J. B., Schroll J., G?tzsche P. C., et al. Underreporting of confl icts of interest in clinical practice guidelines: cross-sectional study. BMC Med Ethics. 2013; 14: 19.
99. Steinbrook R. Controlling confl ict of interest – proposals from the Institute of Medicine. N Engl J Med. 2009; 360: 2160–3.
100. Zinner D. E., Bolcic-Jankovic D., Clarridge B., et al. Participation of academic scientists in relationships with industry. Health Aff. 2009; 28: 1814–25.
101. Lenzer J. French guidelines are pulled over potential bias among authors. BMJ. 2011; 342: d4007.
102. Clinard M. B., Yeager P. C. Corporate Crime. New Brunswick: Transaction Publishers; 2006.
103. Reuters. Factbox – The 20 largest pharmaceutical companies. 2010 Mar 26. Available online at: www.reuters.com/article/2010/03/26/pharmaceutical-mergers-idUSN2612865020100326 (accessed 17 June 2012).
104. Wikipedia. List of countries by GDP (nominal). Available online at: http://en.wikipedia.org/wiki/List_of_countries_by_GDP_(nominal) (accessed 30 June 2012).
105. Annas G. J. Corporations, profi ts, and public health. Lancet. 2010; 376: 583–4.
106. Thomas K., Schmidt M. S. Glaxo agrees to pay $3 billion in fraud settlement. New York Times. 2012 July 2.
107. Khan H., Thomas P. Drug giant AstraZeneca to pay $520 million to settle fraud case. ABC News. 2010 April 27.
108. Brynner R., Stephens T. Dark Remedy: the impact of thalidomide and its revival as a vital medicine. New York: Perseus Publishing; 2001.
109. House of Commons Health Committee. The Infl uence of the Pharmaceutical Industry. Fourth Report of Session 2004–05. Available online at: www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf (accessed 26 April 2005).
110. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000; 283: 373–80.
111. Grill M. Kranke Gesch?fte: wie die Pharmaindustrie uns manipuliert. Hamburg: Rowohlt Verlag; 2007.
112. Ziegler M. G., Lew P., Singer B. C. The accuracy of drug information from pharmaceutical sales representatives. JAMA. 1995; 273: 1296–8.
113. Dana J., Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA. 2003; 290: 252–5.
114. Moynihan R., Heath I., Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ. 2002; 324: 886–91.
115. Campbell E. G. Doctors and drug companies: scrutinizing infl uential relationships. N Engl J Med. 2007; 357: 1796–7.
116. Steinman M. A., Shlipak M. G., McPhee S. J. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med. 2001; 110: 551–7.
117. Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry. Lanham: Rowman & Littlefi eld; 2008.
118. Campbell E. G., Gruen R. L., Mountford J., et al. A national survey of physician-industry relationships. N Engl J Med. 2007; 356: 1742–50.
119. Lenzer J. Many US medical associations and disease awareness groups depend heavily on funding by drug manufacturers. BMJ. 2011; 342: d2929.
120. Campbell E. G., Weissman J. S., Ehringhaus S., et al. Institutional academic industry relationships. JAMA. 2007; 298: 1779–86.
121. Revill J. Doctor accuses drug giant of ‘unethical’ secrecy. Observer. 2005 Dec 4.
122. Steinbrook R. Physician-industry relations – will fewer gifts make a difference? N Engl J Med. 2009; 360: 557–9.
123. Roehr B. US Institute of Medicine report calls for an end to fi rms’ drug and device promotion to doctors. BMJ. 2009; 338: 1100.
124. Steinman M. A., Landefeld C. S., Baron R. B. Industry support of CME – are we at the tipping point? N Engl J Med. 2012; 366: 1069–71.
125. Norris S. L., Holmer H. K., Ogden L. A., et al. Characteristics of physicians receiving large payments from pharmaceutical companies and the accuracy of their disclosures in publications: an observational study. BMC Medical Ethics. 2012; 13: 24.
126. Arnfred C. E., Pedersen L. N., Agger C. [Politicians feel cheated by lobby-doctors]. Jyllandsposten. 2011 Aug 29.
127. Thirstrup S. [Can you sell diseases]? Rationel Farmakoterapi. 2010 Dec.
128. Borg O. [Pill ads are distributed in school yards]. Jyllands-Posten. 2011 Nov 1.
129. Herxheimer A. Relationships between the pharmaceutical industry and patients’ organisations. BMJ. 2003; 326: 1208–10.
130. Rathje M. [Heart Association scares the Danes]. TV2 News. 2012 April 20.
131. Cassidy J. The International Alliance of Patients’ Organizations. BMJ. 2011; 342: d3485.
132. [Danish Association of the Pharmaceutical Industry’s collaboration with patient associations and others in 2010]. 2010. Available online at: www.lifdk.dk/graphics/Lif/Inside%20Lif/2011/09/Medlemmers%20samarbejde%20med%20patientforeninger%20m.v.%202010.pdf (accessed 28 June 2011).
133. Wolfe S. The seven-year rule for safer prescribing. Aust Prescr. 2012; 35: 138–9.
134. Jelinek G. A., Brown A. F. A stand against drug company advertising. Emergency Medicine Australasia. 2011; 23: 4–6.
135. Altman D. G. The scandal of poor medical research: we need less research, better research, and research done for the right reasons. BMJ. 1994; 308: 283–4.
136. Lexchin J., Light D. W. Commercial infl uence and the content of medical journals. BMJ. 2006; 332: 1444–7.
137. Lundh A., Barbateskovic M., Hrybjartsson A., et al. Confl icts of interest at medical journals: the infl uence of industry-supported randomised trials on journal impact factors and revenue – cohort study. PLoS Med. 2010; 7: e1000354.
138. Smith R., Roberts I. Patient safety requires a new way to publish clinical trials. PLoS Clin Trials. 2006; 1: e6.
139. Clinical knowledge: from access to action. Lancet. 2008; 371: 785.
140. Schwartz L., Woloshin S., Moynihan R. Who’s watching the watchdogs? BMJ. 2008; 337: a2535.
